Group items tagged

Ayukawa F, Shibuya H, Yoshimura RI, Watanabe H, Miura M. Curative Brachytherapy for Recurrent/Residual Tongue Cancer. Strahlenther Onkol. 2007 Mar;183(3):133-137. PMID: 17340071 [PubMed - as supplied by publisher]

Cancer immunotherapies, including cancer vaccines, are novel investigational cancer therapies. In contrast to chemotherapy and radiotherapy regimens that are often associated with severe side effects, cancer immunotherapy stimulates the body's immune system and natural resistance to cancer, thus offering a gentler means of cancer treatment that is less damaging to the rest of the body. Surgery is generally (but not always) performed, prior to immunotherapy, to remove most of the tumor (Hanna MG, Jr. et al 2001; Jocham D et al 2004). Vaccination or immunotherapy prompts the immune system to kill residual cancer cells that persist after surgery and could result in the cancer recurring.